BofA raised the firm’s price target on Metsera (MTSR) to $50 from $45 and keeps a Buy rating on the shares. Following the Q2 report, the firm is updating estimates, including changes in spending assumptions, and rolls forward its base valuation year from 2025 to 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera, Inc. Reports Q2 2025 Financial Progress
- Metsera, Inc. Poised for Growth: Anticipated Catalysts and Clinical Trial Success Drive Buy Rating
- Metsera reports Q2 EPS (66c), consensus (68c)
- Metsera price target raised to $45 from $38 at BofA
- Metsera, Inc.: Buy Rating Affirmed Amid Promising Clinical Data and Strategic Positioning